论文部分内容阅读
目的 Frat1蛋白在食管癌、卵巢癌、中枢神经系统肿瘤中有异常表达,但是在非小细胞肺癌(NSCLC)组织中的表达情况研究甚少,其表达情况与患者预后之间是否存在相关性等尚不清楚。方法用免疫组化SP法对100例原发性NSCLC患者手术标本中Frat1的表达进行检测。结果 Frat1蛋白在肺癌组织中的表达明显增强,Frat1的阳性表达与分化程度(P=0.022)、淋巴结转移(P=0.016)和TNM分期正相关(P=0.011),并且Frat1阳性表达患者的术后生存时间(41.651±4.445个月)明显低于阴性者(74.222±6.844个月,P=0.035)。结论 Frat1在NSCLC中过表达,与肺癌的侵袭和转移等恶性表型有关,Frat1的异常表达提示NSCLC患者的不良预后。
Purpose Frat1 protein is abnormally expressed in esophageal cancer, ovarian cancer and central nervous system tumors, but little is known about the expression of Frat1 in non-small cell lung cancer (NSCLC) tissues. Is there any correlation between its expression and prognosis? still not clear. Methods Immunohistochemical SP method was used to detect the expression of Frat1 in 100 surgical specimens of patients with primary NSCLC. Results The expression of Frat1 protein in lung cancer tissues was significantly increased. The positive expression of Frat1 was positively correlated with the differentiation degree (P = 0.022), lymph node metastasis (P = 0.016) and TNM stage (P = 0.011) Post-survival time (41.651 ± 4.445 months) was significantly lower than negative (74.222 ± 6.844 months, P = 0.035). Conclusions Frat1 is overexpressed in NSCLC and is associated with malignant phenotypes such as invasion and metastasis of lung cancer. Abnormal expression of Frat1 may be associated with poor prognosis in patients with NSCLC.